Preprint Communication Version 1 Preserved in Portico This version is not peer-reviewed

Latent Tuberculosis Infection in Patients with Multiple Sclerosis

Version 1 : Received: 17 April 2020 / Approved: 17 April 2020 / Online: 17 April 2020 (15:34:17 CEST)

How to cite: Pastor Bandeira, I.; Figueiredo da Silva, C.; Marchi Martin, M.E.; Figueiredo da Silva, G.; Parolin, L.F.; Melo, L.H.; Magno Goncalves, M.V. Latent Tuberculosis Infection in Patients with Multiple Sclerosis. Preprints 2020, 2020040305 (doi: 10.20944/preprints202004.0305.v1). Pastor Bandeira, I.; Figueiredo da Silva, C.; Marchi Martin, M.E.; Figueiredo da Silva, G.; Parolin, L.F.; Melo, L.H.; Magno Goncalves, M.V. Latent Tuberculosis Infection in Patients with Multiple Sclerosis. Preprints 2020, 2020040305 (doi: 10.20944/preprints202004.0305.v1).

Abstract

Tuberculosis (TB) is an infectious-contagious disease caused by M. tuberculosis (Koch’s bacillus). About one-quarter of the world’s population is infected with that bacillus and at risk of developing TB disease. Latent tuberculosis corresponds to people who have been infected by TB bacteria but are not (yet) ill. The most vulnerable population to TB activation includes HIV infected, drug abuse and autoimmune disease patients. Multiple Sclerosis (MS) is a chronic and autoimmune neurological disease caused by lymphocytic infiltration. Its prevalence worldwide is 22.2 million cases of MS. There is a relation between TB and MS: due to immunomodulation or immunosuppression treatment of MS (reactivation of latent infection), or due to the intense inflammatory response before the infection of the bacillus (increased susceptibility to the development of autoimmune diseases). Screening for TB includes complete patient history, physical exam, chest radiography, and Tuberculin Skin Test or IGRA (Interferon Gamma Release Assay). This investigation is suggested when MS drugs (immunomodulatory and immunosuppressant medications) are prescribed. If a patient has positive results, the treatment for MS should not be delayed for the finishing TB treatment. In this paper, considering the high prevalence of tuberculosis, we recommend that TB screening should be also done at the moment of Multiple Sclerosis diagnosis.

Subject Areas

multiple sclerosis; tuberculosis; immunosuppressive therapy; Latent tuberculosis

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.